Search...
Delivery delays mean that the second quarter and thus the full year 2025/26 will be weaker than expected
I'm PortAI, I can summarize articles.
EQL Pharma has reported delivery delays from suppliers in Q2, leading to lost sales and a weaker outlook for the full year 2025/26, with expected growth closer to 15% instead of 30%. Sales for Q2 are projected to be just under 90 MSEK, reflecting single-digit growth year-over-year. The EBITDA margin is anticipated to be around 20%. Launches planned for Q2 are postponed to late Q3 or early Q4. The company reassures that these issues are temporary and do not impact its five-year targets. Full results will be disclosed on November 5, 2025.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments